The practical guide to medical device advertising compliance in Australia 2025

Medical device advertising occupies a distinctive position in Australian health compliance. Unlike medicines, devices are not assessed by the TGA for clinical efficacy before market entry — the regulatory process for most devices verifies essential principles compliance and manufacturing quality, not whether the claimed benefit is as strong as the advertising suggests. This creates a compliance gap that the advertising framework is designed to fill: the Therapeutic Goods Advertising Code and the Australian Consumer Law together restrict device advertisers to claims that are supported by adequate evidence, accurately describe the device's intended purpose, and do not mislead consumers about benefits or risks.

The enforcement record is significant. TGA issued 4,806 removal requests in 2023–24 and 147 infringement notices totalling $2.20M. Medical devices — particularly consumer-facing devices in the wellness, wearables, and therapeutic equipment categories — account for a material proportion of TGA advertising enforcement. The most common violation is not an egregious fabricated claim: it is a genuine device with a real benefit that is described in advertising in terms that exceed what the device's classification and ARTG entry will support.

Medical device advertising sits across four distinct regulatory layers that apply simultaneously.

Therapeutic Goods Act 1989 — ARTG registration requirement
A medical device cannot be advertised to consumers in Australia unless it is included on the ARTG. This is a pre-condition to all lawful advertising activity. The ARTG entry specifies the device's classification, its approved intended purpose, its sponsor, and (for higher-class devices) the clinical evidence base. Advertising that references a device not included on the ARTG is illegal. Advertising a device for a purpose not covered by its ARTG entry — even if the device is lawfully registered — is also a breach.

Therapeutic Goods Advertising Code 2021 — claim requirements
The Advertising Code applies to consumer-directed advertising of medical devices. Key requirements:

• Claims must not exceed the device's ARTG-approved intended purpose (s.8)
• Mandatory statements must appear in consumer advertising: the ARTG listing number, sponsor name, and where relevant, "follow the instructions for use" (ss.14–16)
• Testimonials from users attributing health outcomes to the device are prohibited in consumer advertising (s.17)
• Restricted representations — claims relating to the treatment or prevention of serious conditions — require pre-approval from the Secretary (ss.20–21)

Therapeutic Goods (Medical Devices) Regulations 2002 — essential principles
The essential principles require that device advertising accurately describes the device's intended purpose and does not mislead about performance, safety, or essential specifications. Essential principles compliance is not a substitute for Advertising Code compliance — both apply independently.

Australian Consumer Law — misleading conduct and safety representations
All device advertising is subject to ACL s.18 (misleading or deceptive conduct) and s.29 (false representations about goods). For medical devices, ACL scrutiny is particularly focused on: efficacy claims that imply a degree of benefit the evidence does not support; safety claims that omit material risks; and comparative claims ("superior to", "more effective than") that cannot be substantiated.

The most fundamental requirement of medical device advertising compliance is that the device's intended use as described in advertising must match — and not exceed — the intended purpose recorded on the device's ARTG entry.

What "intended purpose" means. The ARTG entry for a medical device records the specific therapeutic purpose for which the device has been included on the register. For a Class I TENS (transcutaneous electrical nerve stimulation) device, the intended purpose might be: "for temporary relief of pain associated with musculoskeletal conditions." An advertisement describing the same device as "the clinically proven way to eliminate chronic pain" exceeds the intended purpose on three counts: it implies permanent rather than temporary relief, it implies elimination rather than temporary reduction, and the phrase "clinically proven" implies a standard of evidence associated with the intended purpose that the device's ARTG entry does not necessarily reflect.

How advertising copy commonly exceeds intended purpose:

Condition scope expansion. A device cleared for musculoskeletal pain is advertised as effective for fibromyalgia, rheumatoid arthritis, or other conditions not listed in its intended purpose. The device may genuinely help some users with these conditions — but advertising cannot claim benefits beyond the ARTG-approved scope.

Mechanism overstating. A wound care dressing approved as an interface layer that "may support wound healing" is advertised as "accelerates healing by triggering cellular regeneration." The advertising copy has transformed a modest functional claim into a mechanistic efficacy statement that requires a higher standard of evidence.

Performance quantification. Adding specific performance numbers to a device's intended purpose — "reduces pain by 60%", "improves recovery time by 3x" — requires clinical evidence specific to the device, not general category evidence. An advertising claim that quantifies performance must be substantiated by evidence that demonstrates that performance for that device.

Medical device classification in Australia determines the pre-market regulatory pathway and directly affects the standard of evidence that can be claimed in advertising.

Class I — lowest risk
General-purpose devices: bandages, crutches, non-sterile examination gloves, basic wearables without diagnostic claims. Class I devices are not assessed by the TGA for clinical efficacy — they are included on the ARTG through a self-declaration process. Advertising for Class I devices cannot claim clinical efficacy that has not been substantiated by evidence held by the sponsor. The TGA's failure to assess efficacy does not create a permission to claim efficacy without evidence.

Class IIa — lower-moderate risk
Contact lenses, hearing aids, blood glucose monitoring systems, non-invasive monitoring devices. Class IIa devices require conformity assessment, but TGA assessment focuses on safety and manufacturing quality. Advertising efficacy claims for Class IIa devices must be based on evidence the sponsor holds and must not exceed what that evidence supports.

Class IIb — higher-moderate risk
Infusion pumps, orthopaedic implants, surgical lights, devices that administer medicines. Class IIb devices undergo more extensive conformity assessment. Advertising is subject to the Advertising Code in the same way as Class IIa, but the evidence base for Class IIb claims will typically be clinical studies — advertising must accurately characterise what those studies show and must not extrapolate beyond their scope.

Class III — highest risk
Active implantable devices, cardiac pacemakers, breast implants, drug-eluting stents. Class III devices are assessed by a TGA-recognised conformity assessment body and are subject to the highest regulatory scrutiny. Consumer-directed advertising for Class III devices is effectively prohibited in most cases — advertising for implantable devices is directed to healthcare professionals, not consumers. Any consumer-facing content about Class III devices should be treated as requiring legal review before publication.

Certain device categories require mandatory warnings or contraindication statements in consumer-facing advertising. These are not optional — their omission is a breach of the Advertising Code.

Devices with mandatory warning requirements include:

Wearable monitoring devices making diagnostic claims. A consumer wearable that claims to detect atrial fibrillation, blood oxygen saturation, or other diagnostic indicators must include appropriate statements about the limitations of consumer-grade measurement. Advertising that presents these devices as equivalent to clinical diagnostic tools is both a potential Advertising Code breach and an ACL misleading conduct issue.

Electrical stimulation devices. TENS units, EMS devices, and similar electrical stimulation products marketed for pain relief or muscle stimulation require contraindication warnings for users with pacemakers, implantable defibrillators, and during pregnancy. Advertising that omits these warnings when consumers are the target audience may be non-compliant.

Surgical and invasive devices advertised to consumers. Where Class IIb or Class III device characteristics are referenced in consumer-facing promotional materials — for example, breast augmentation advertising that describes implant characteristics — contraindication and risk information is required to provide a balanced picture. Advertising that presents only benefits without material risks is misleading under the ACL.

"Clinically proven" is one of the most frequently misused phrases in medical device advertising. It implies a standard of evidence — controlled clinical trials, peer-reviewed results, regulatory-accepted evidence — that most consumer device advertising cannot substantiate.

The evidence standard for device advertising claims. The TGA requires that advertising claims for medical devices be substantiated by evidence that is consistent with the claim. For a claim that a device "reduces pain by X%", the substantiating evidence must be: a study of the specific device (not the device category), in a population comparable to the advertising's target audience, using validated outcome measures, with a sample size adequate to support the stated figure. General category evidence does not substantiate specific device claims.

Comparative claims. "Better than", "more effective than", "the leading device for" — these require head-to-head comparative evidence against the specific named comparator. In the absence of that evidence, comparative claims are ACL breaches. The phrase "leading" implies comparative superiority that must be demonstrated by market data or comparative clinical evidence.

Consumer testimonials. The Advertising Code s.17 prohibition on testimonials applies to medical devices in the same way as therapeutic goods. A user testimonial that attributes a health outcome to a medical device — "this device eliminated my knee pain" — is prohibited in consumer advertising. This extends to reviews on brand-owned platforms, influencer content that describes therapeutic outcomes, and social media content curated and promoted by the device sponsor.

CompliGUARD reviews medical device marketing content — intended-use statements, efficacy claims, classification-appropriate language, mandatory warnings, and testimonial usage — against TGA · AHPRA · FSANZ · ACCC requirements simultaneously. For ARTG-listed devices, CompliGUARD cross-references advertising copy against the device's recorded intended purpose, flagging claims that exceed the registered scope, omit mandatory statements, or make evidence-unsupported efficacy claims. Every review returns a clause-cited compliance report, a risk rating, and a compliant rewrite. Every review is stored in a tamper-evident audit vault.

CompliGUARD provides compliance insights based on TGA, FSANZ, ACCC and AHPRA guidance as current at the time of review. The Therapeutic Goods Advertising Code is currently under formal review by the TGA (2025–26). This output does not constitute legal advice.

• Publishing without checking the complete advertisement’s overall impression.
• Treating one regulator’s checklist as coverage for every applicable framework.
• Failing to retain evidence showing what was reviewed and approved before publication.

CompliGUARD reviews the complete advertisement against TGA · AHPRA · FSANZ · ACCC requirements, identifies clause-level risks, proposes compliant wording, and retains the result in an audit trail before publication.